Santhera Pharmaceuticals and Reveragen BioPharma are gearing up to submit vamorolone to the US regulator as a new Duchenne muscular dystrophy treatment by the end of this year, but have also just announced the start of Phase II study of the drug in the related Becker muscular dystrophy (BMD).
Caused by the mutations in the same gene as Duchenne, which cause a loss of the muscle-building protein dystrophin, BMD is usually milder and the progressive muscle weakness slower